Company intelligence / Profile preview

Dr. Frank Arguello Cancer Clinic

Bethesda, Maryland, United Statesatavisticchemotherapy.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The clinic is conducting a clinical trial (NCT02366884) for "Atavistic Chemotherapy" based on Dr. Arguello's theory of "Atavistic Metamorphosis." The treatment claims to target and eliminate cancer cells selectively using combinations of drugs conventionally used against bacterial, fungal, and protozoal cells. The trial claims patients can expect significant clinical response within three weeks and potential complete cancer eradication within six months[1][4].

Therapeutic areas: Oncology
Modalities: Combination of FDA-approved drugs (specific drugs not disclosed)
Industry: Non-Academic Healthcare

Drug pipeline

1 asset

Atavistic Chemotherapy

Phase 2

Indications: Advanced cancer, Metastatic cancer

Beyond the preview

Go deeper on Dr. Frank Arguello Cancer Clinic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dr. Frank Arguello Cancer Clinic.

Explore the full profile